Seattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $84.1 million versus the consensus estimate of $82.67 million.

ADCETRIS sales in the third quarter of $59.1 million, an increase from $48.2 million in the third quarter of 2014. For the year-to-date, ADCETRIS sales were $163.0 million, compared to $131.7 million for the year-to-date period in 2014, a 24 percent increase

For earnings history and earnings-related data on Seattle Genetics (SGEN) click here.